… -affinity TCRs for TCR gene therapy also comes with a toxicity risk. … The expression of
MAGE-A12 in the brain most likely … of the TCR-T cells was evaluated by IFN-γ production after an …

… patients experiencing tumor regression [10]. Evidence of anti-… was still present on tumor
samples after TCR therapy, so antigen … in the brain which likely triggered a fatal TCR-mediated …

… after 5+ years of follow-up. This study highlighted combination … tumor regression and a
persistence of transduced T cells using autologous anti-MAGE-A3 112–120/HLA-A*0201 TCR (…

… the induction of cytokine release syndrome and neurological toxicity. Another drawback of this
… Further to this study, a long-term follow-up study was carried out by the same investigators …

… Two out of 17 patients experienced disease regression and … 3–5 after cell infusion. There
was noted to be on target off-… the safety and efficacy of anti-MAGE-A3 TCR engineered T cells. …

… Cancer regression in patients after transfer of genetically engineered lymphocytes. Science.
… Cancer regression and neurological toxicity following anti- MAGE- A3 TCR gene therapy. J …

… Cancer testis antigens (CTAs) are considered attractive targets for T cell receptor (TCR)-based
cellular therapies … on-target/off-cancer toxicity. Melanoma associated antigen 1 (MAGE-A1…

… after TIL infusion. Of the 20 enrolled patients, most of the patients had initial tumor regression
… treated with an anti-MAGE-A3 TCR in 2013,46 though several of the patients experienced …

… The risk is thought to be higher with T-cell receptors (TCRs) that are modified after isolation
… next tested brain tissue sections from 8 postmortem donors (5 normal and 3 cancer patient …

… toxicities, ranging from minutes to months following the … , engineering T cell receptor (TCR)
therapy, chimeric antigen … particularly profound neurologic toxicity and systemic toxicity from …